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Abstract 
Novel signaling molecule(s) that induce lankacidin and lankamycin production in 
Streptomyces rochei were extracted from the culture filtrate and purified by Sephadex 
LH20 and silica gel chromatography with the help of bioassay. Chiral HPLC and 
ESI-MS analyses indicated the presence of two active components, SRB1 and SRB2, 
and their molecular formulae were established to be C15H24O5 and C16H26O5, 
respectively. Based on extensive NMR analysis, SRB1 and SRB2 were determined to be 
2-(1’-hydroxyl-6’-oxo-8’-methylnonyl)-3-methyl-4-hydroxybut-2-en-1,4-olide and 
2-(1’-hydroxyl-6’-oxo-8’-methyldecyl)-3-methyl-4-hydroxybut-2-en-1,4-olide, 
respectively. These structures were finally confirmed by chemical synthesis and the 
absolute configuration of C-1’ was determined to be R. The synthetic 1’R-isomers 
induced production of lankacidin and lankamycin at around 40 nM concentration. Thus, 
SRB1 and SRB2 are distinct from the well-known 2,3-disubstituted γ-butyrolactone 
molecules such as A-factor, virginia butanolide, and SCB1 and belong to the 
γ-butenolide family following avenolide which has been recently isolated from 
Streptomyces avermitilis. 
 
Introduction 
The filamentous soil bacteria, Streptomyces, are characterized by the ability to 
produce a wide variety of secondary metabolites including antibiotics. In many 
Streptomyces species, small diffusible signaling molecules control antibiotic production 
and morphological differentiation.[1,2] The well-studied family of signaling molecules 
identified up to date have a 2,3-disubstituted γ-butyrolactone skeleton and are active at 
nanomolar concentrations.[3] The most extensively characterized molecule is A-factor 
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(2-isocapryloyl-3R-hydroxymethyl-γ-butyrolactone) (Scheme 1A), which is responsible 
for streptomycin production and morphological differentiation in Streptomyces 
griseus.[4] When A-factor produced in a growth-dependent manner reaches a critical 
concentration, it binds to a specific receptor protein ArpA, and then the A-factor/ArpA 
complex dissociates from the promoter region of adpA, a global transcriptional activator 
gene. The derepressed gene product AdpA binds to its target genes to activate 
streptomycin production and morphological differentiation.[5] On the top of this 
regulatory cascade, the afsA gene encodes a key enzyme in A-factor biosynthesis.[6,7] 
Additional γ-butyrolactone-type signaling molecules and their specific receptors were 
identified in several Streptomyces species, including Streptomyces coelicolor A3(2),[8] 
Streptomyces virginiae,[9] and Streptomyces lavendulae FRI-5.[10] The 
γ-butyrolactone-type signaling molecules were classified into three major groups based 
on the reduction state and the stereochemistry of C-1’ (Scheme 1A); (1) the 1’-keto type 
(e.g. A-factor in S. griseus), (2) the 1’R-hydroxyl type (SCB1 in S. coelicolor A3(2)), 
and (3) the 1’S-hydroxyl type (virginia butanolides in S. virginiae). Recently, novel 
signaling molecules were identified in S. coelicolor and Streptomyces avermitilis. A 
furan-type signaling molecule, methylenomycin furan (Scheme 1A), was shown to 
induce methylenomycin production in S. coelicolor.[11] A 4-monosubstituted butenolide 
named avenolide (Scheme 1A) induces avermectin production in S. avermitilis with a 
minimum inducing concentration of 4 nM.[12] Thus, various type of signaling molecules 
are involved in controlling antibiotic biosynthesis in Streptomyces species. 
   Streptomyces rochei strain 7434AN4 carries three linear plasmids (pSLA2-L, -M, 
and -S) and produces two structurally unrelated polyketide antibiotics, lankacidin and 
lankamycin (Figure S1).[13] Lankacidin and lankamycin inhibit peptide synthesis 
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synergistically by targeting neighboring sites in the ribosome.[14] The biosynthetic gene 
clusters of these antibiotics are located on the giant linear plasmid pSLA2-L.[15-17] In 
addition, many regulatory genes were identified on pSLA2-L, including a synthesis 
gene of the signaling molecule (srrX), six tetR-type repressor genes (srrA-F), and three 
SARP (Streptomyces antibiotic regulatory protein) genes (srrY, srrZ, and srrW). We 
revealed that srrX and srrA constitute the signaling molecule/receptor system in S. 
rochei.[18] Extensive mutational and transcriptional analyses revealed that the SARP 
gene srrY is a target of SrrA and that the signaling pathway goes from srrX through srrA 
to srrY, leading to lankacidin and lankamycin production.[19] Furthermore, it was shown 
that SrrY directly activates transcription of the second SARP gene srrZ for LM 
production.[20] In spite of these accumulated data on the regulatory cascade of antibiotic 
production in S. rochei 7434AN4, the signaling molecule(s) themselves have not been 
isolated.  Here we report the isolation, structural elucidation, and biological activity of 
the signaling molecules termed “SRBs (Streptomyces rochei butenolides)” that induce 
lankacidin and lankamycin production at a nanomolar concentration. 
 
Results 
Isolation of SRBs 
   S. rochei KA61, a disruptant of the SARP-family activator gene srrY, was used to 
isolate the SRB molecules. This strain does not produce lankacidin or lankamycin due 
to a shutdown of the regulatory cascade downstream of srrY, which improves the 
isolation efficiency of the SRB molecules without disturbance of antibiotics. A 160-liter 
culture of strain KA61 was grown in a 200-liter jar fermenter at 28°C for 43 h. The 
culture filtrate was passed through an Amberlite® XAD16 column to absorb 
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hydrophobic metabolites including SRBs. The column was extracted with ethyl acetate 
(EtOAc), and the resulting oil (18 g) was purified by silica gel chromatography with 
hexane-EtOAc (2:1 to 1:2, v/v). Each fraction was subjected to bioassay to check its 
antibiotic-inducing activity. The active fractions were combined and purified by 
Sephadex LH20 with methanol as eluent. Then, the active fractions were collected and 
further purified by series of silica gel chromatography with the following three solvent 
systems to give a single spot on TLC (Rf = 0.20 in hexane-EtOAc=1:1, v/v); 
CHCl3-methanol (50:1-30:1, v/v), toluene-EtOAc (2:1-1:1, v/v), and hexane-EtOAc 
(2:1-1:1, v/v). No other fractions showed any inducing activity, indicating that the 
purified component is an inducing factor of lankacidin and lankamycin in S. rochei.  
   The active component was further analyzed by chiral HPLC (TCI Chiral MB-S 
column; macroporous silica gel coated with optically active N-substituted 
polymaleimides) using 10% aqueous acetonitrile as mobile phase (flow rate; 1.0 
mLmin–1) with detection at 210 nm. In contrast to the results with HPLC and TLC, two 
peaks were detected at 9.1 min (SRB1) and 17.3 min (SRB2) (Figure 1A). However, 
due to a limiting amount of two compounds available (total ~250 µg; later estimated by 
UV absorbance), structural analysis was carried out as a mixture. ESI-MS analysis also 
indicated the presence of SRB1 and SRB2 in the ratio 1:1 (Figure 1B). Their molecular 
formulae were established to be C15H24O5 for SRB1 and C16H26O5 for SRB2, 
suggesting that SRB1 and SRB2 are homologs with one methylene difference. 
Concerning to the HPLC chromatogram of SRBs (Figure 1A), it is noteworthy that their 
retention times differed by 8.2 min. A similar relationship was observed in the S. 
coelicolor signaling molecules, SCB1 and SCB3 (Scheme 1A): SCB1 (iso-type C8 side 
chain) eluted at 22-23 min, whereas SCB3 (anteiso-type C9 side chain) eluted at 40-48 
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min.[21] 
Structural elucidation of SRBs 
   The 13C NMR and HMBC spectra of the mixture of SRB1 and SRB2 revealed two 
carbonyl groups (C-1 and C-6’; δC 170.7 and 213.1) and one C=C double bond (C-2 
and C-3; δC 129.4 and 157.1) (Figure 1D). No olefinic protons were observed in the 1H 
NMR spectrum (Figure 1C), suggesting that the C=C double bond was fully substituted. 
Taking account of the degree of unsaturation, the cyclic skeleton in SRBs was deduced. 
A strong absorbance at 1,750 cm–1 in the IR spectrum indicated the presence of an 
α,β-unsaturated γ-lactone ring. The singlet H-5 protons at δH 2.08 were assigned to a 
methyl group at C-3 (δC 157.1) by HMBC of the H-5 protons to C-3 (Figure 1E-I). The 
H-5 protons showed long range HMBC correlations with the C-4 methine carbon (δC 
98.7) and the C-2 quaternary carbon (δC 129.4). The C-4 carbon harbors a highly 
deshielded broad-singlet proton (δH 5.88), indicating that C-4 is hydroxylated. 
Furthermore, the broad-singlet H-4 proton showed a HMBC correlation with the C-1 
carbonyl carbon (δC 170.7). The H-5 protons showed moderate NOEs on the deshielded 
H-1’ proton (δH 4.50) of the alkyl side chain as well as on H-4. From these data, a 
2,3-disubstituted γ-hydroxybutenolide ring was deduced as a partial structure, where 
C-3 was substituted with a methyl group and C-2 with an alkyl side chain (Figure 1E-I). 
The broad-singlet signal of H-4 implied that two compounds exist as mixtures of 
interconverting epimers at C-4. These assignments showed a good agreement with those 
of known 2,3-disubstituted γ-hydroxybutenolides (R = isopropyl or sec-butyl; Figure 
1E-I), which were previously isolated from Streptomyces antibioticus Tü99.[22]  
   The partial structure of SRBs indicated that the alkyl side chains branched at C-2 
have the formulae C10H19O2 for SRB1 and C11H21O2 for SRB2. The C-6’ carbonyl 
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carbon at δC 213.1 was assigned to a ketone, which showed HMBC correlations with 
proton signals at δH 2.26 (doublet), 2.18 (double-doublet), and 2.37-2.40 (multiplet) 
(Figure 1D). These signals correspond to the methylene protons; δH 2.26 at δC 52.0 
(C-7’ of SRB1) (Figure 1E-II), δH 2.18 and 2.37 at δC 50.1 (C-7’ of SRB2) (Figure 
1E-III), and δH 2.40 at δC 42.6 (C-5’ of SRB1 and SRB2) (Figures 1E-II and -III). 
These spectral data indicates that the methylene groups (C-5’ and C-7’) at both sides of 
C-6’ have a different chemical environment. Concerning to SRB1, the doublet H-7’ 
proton (δH 2.26) showed a 1H-1H COSY correlation with proton at δH 2.10, which in 
turn connected to two methyl groups H-9’ and H-9’’ at δH 0.89-0.90. Thus, a partial 
structure of the alkyl chain of SRB1 was elucidated as shown in Figure 1E-II. 
Concerning to SRB2, the double-doublet H-7’a proton (δH 2.18) showed 1H-1H COSY 
correlations with signals at δH 2.37 and δH 1.90, the former being assigned to a geminal 
H-7’b proton by HMQC experiment. The latter proton (δH 1.90) connected to C-8’ 
showed a further 1H-1H COSY correlation with the H-9’’ methyl protons (δH 0.86) 
(Figure 1E-III). In addition, the C-8’ carbon (δC 30.7) showed HMBC correlations with 
the double-doublet H-7’a proton and the H-10’ methyl protons (δH 0.86), the latter of 
which showed a 1H-1H COSY correlation with the H-9’’ methylene protons (δH 1.2-1.3). 
These assignments led to a partial structure of the alkyl chain of SRB2 as illustrated in 
Figure 1E-III. Although further assignments of additional three methylene groups 
attached to C2’-C4’ of SRB1 and SRB2 were difficult due to overlapping signals, SRB1 
and SRB2 were assigned to be 
2-(1’-hydroxyl-6’-oxo-8’-methylnonyl)-3-methyl-4-hydroxybut-2-en-1,4-olide (1) and 
2-(1’-hydroxyl-6’-oxo-8’-methyldecyl)-3-methyl-4-hydroxybut-2-en-1,4-olide (2). Both 
compounds contain a 2,3-disubstituted γ-hydroxybutenolide skeleton, which is distinct 
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from that of the known γ-butyrolactone molecules such as A-factor, virginia butanolide, 
and SCB1 (Scheme 1).  
Synthesis of SRB molecules 
  To confirm the proposed structures of 1 and 2 and determine their C-1’ configurations, 
the 1’R-isomers (1a and 2a) and the 1’S-isomers (1b and 2b) were synthesized as 
shown in Scheme 2. The readily available 1-(benzyloxy)-6-hexanol (3)[23] was oxidized 
by pyridinium chlorochromate (PCC) to give aldehyde 4 in 81% yield. For the synthesis 
of the alkyl chains of 1a and 1b (Scheme 2A), the aldehyde 4 was coupled with the 
Grignard reagent isobutylmagnesium bromide to give a C10 unit 5 in 81% yield, in 
which a newly generated hydroxyl group was oxidized by PCC to afford ketone 6 in 
82% yield. Protection of the ketone group in 6 with ethylenedioxybis(trimethylsilane), 
deprotection of the benzyl group, and subsequent oxidation with PCC afforded aldehyde 
7 in 64% yield (3 steps). Enantiomerically pure 
3-methyl-4-(L-menthyloxy)but-2-en-1,4-olide (8) was prepared by condensation of 
propanal with glyoxylic acid and L-menthol, followed by two-stage recrystallizations 
from petroleum ether.[24,25] The key coupling reaction between the anion derived from 8 
with lithium diisopropylamide (LDA) and the aldehyde 7 provided a diastereomeric 
mixture of 9a and 9b in the ratio 2:1 in 31% yield. The large protecting group 
(L-menthyl) at the C-4 hydroxyl of 8 prevented deprotonation of the more acidic H-5 
proton,[26] leading to the production of a desired 2,3-disubstituted 
γ-(L-menthyloxy)butenolide. The diastereomeric mixture of 9a and 9b was separated by 
repeated runs of flash chromatography with hexane-ethyl acetate. Each of the purified 
compounds had 94% diastereomeric purity as judged from two well-separated 
hemiacetal H-4 proton signals in the 1H NMR spectra (δH 5.69 for 9a and δH 5.71 for 
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9b). The C-1’ configurations of these compounds were determined from the ∆δ (δS – 
δR) values of their (S)- and (R)-α-methoxy-α-(trifluoromethyl)-α-phenyolacetate 
(MTPA) ester derivatives.[27] Characteristic H-4 and H-5 proton signals in the 
γ-butenolide moiety of 9a showed distinct negative ∆δ values (–25 and –98 Hz, 
respectively), while the H-2’ proton showed a slightly positive value (+5 Hz). Thus, the 
C’-1 configuration of 9a was determined to be R, while that of 9b is S. Finally, 
deprotection of the L-menthyl and 1,3-dioxolane groups in 9a and 9b was performed 
simultaneously by boron tribromide to afford SRB1a (1a) and SRB1b (1b) in 52% and 
63% yields, respectively. 
   SRB2a (2a) and SRB2b (2b) were synthesized in a similar way for 1a and 1b but a 
different Grignard reagent, (S)-(2-methylbutyl)magnesium chloride, was used for 
construction of a C11 unit 10 (Scheme 2B).  
   The retention times of SRB1 and SRB2 (9.1 and 17.3 min) on a chiral HPLC 
column (mobile phase; 10% aqueous acetonitrile containing 0.1% trifluoroacetic acid) 
at a flow rate of 1.0 mLmin–1 were identical to those of the synthetic 1’R-isomers 1a 
and 2a, whereas the synthetic 1’S-isomers 1b and 2b eluted slightly earlier at 8.7 and 
16.6 min (Figure 2A). Furthermore, the natural SRBs showed a positive optical rotation 
value ([α]D22 = +17.5), which was in good agreement with that of the synthetic 
1’R-isomers (+18.4 for 1a, +22.4 for 2a). The synthetic 1’S-isomers exhibited a 
negative value for the optical rotation (–9.32 for 1b, –5.71 for 2b). Consequently, the 
absolute C-1’ configuration of SRB1 and SRB2 were determined to be R (Scheme 1B). 
As shown in Figure 2B, the spectra of the natural SRBs showed a good agreement with 
those of the synthetic compounds 1a and 2a. In the 1H and 13C NMR spectra of the 
synthetic SRBs (1a, 1b, 2a, 2b), small separate resonances (∆δ < 0.03 ppm in 1H NMR 
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and ∆δ < 0.3 ppm in 13C NMR) are observed due to the presence of interconverting 
epimers at C-4 (Table 1). These hemiacetalic epimers interconvert rapidly[28] and were 
inseparable even on the chiral HPLC. 
Biological activity of SRB molecules 
  The minimum concentration of the synthetic SRBs necessary for antibiotic 
production was determined by bioassay. The 1’R-isomers 1a and 2a showed an inducing 
activity at 42 and 40 nM, while the 1’S-isomers 1b and 2b were active at 660 and 630 
nM, respectively. The value of 1a and 2a corresponded to the level of the inducing 
activity of natural SRBs (approximately 50 nM). The 1’S-isomers (1b and 2b) showed 
much lower activity (around 6%) compared with the 1’R-isomers, suggesting that the 
1’R configuration is important for antibiotic-inducing activity. In this respect, we cannot 
exclude the possibility that the low inducing activity of 1b and 2b is due to a 
contamination of 1a and 2a. The average yield of SRBs in strain KA61 was around 6 µg 
per liter of the culture. The metabolic profiles of strain KA20, a srrX-srrB double 
mutant, separately supplemented with SRB1 and SRB2 were comparable (Figure 3), 
suggesting that both SRB1 and SRB2 play an equal role to induce lankacidin and 
lankamycin production in S. rochei.  
 
DISCUSSION 
   Two signaling molecules, SRB1 and SRB2, that induce production of lankacidin and 
lankamycin in S. rochei 7434AN4 were isolated, and structure-determined. The SRB 
molecules contain a 2,3-disubstituted γ-hydroxybutenolide skeleton. Structurally related 
butenolides have been isolated from S. antibiotics Tü99 as antibiotics, which exhibited a 
moderate antimicrobial activity against Pseudomonas aeruginosa.[22] About 60% of 
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Streptomyces species use γ-butyrolactone-type signaling molecules to induce antibiotic 
production,[29] and fourteen of this type molecules have been hitherto identified.[3,21] 
Recently, novel types of signaling molecules were isolated from several Streptomyces 
species. A furan-type signaling molecule, methylenomycin furan, was identified as an 
autoregulator for methylenomycin production in S. coelicolor A3(2).[11] In addition, 
avenolide, a novel 4-monosubstituted γ-butenolide-type molecule was identified as an 
inducing factor for avermectin production in S. avermitilis.[12] It is noteworthy that the 
avaR gene (sav2269) in S. avermitilis, which encodes a homolog of the AfsA-family 
proteins, is not involved in avenolide production. We have not determined the 
stereochemistry of C-8’ of SRB2. Nevertheless the S configuration of C-8’ in 2 is more 
plausible from the following evidences. 8-Methyldecanoyl-ACP, a possible biosynthetic 
intermediate of 2, is synthesized by condensation of four malonyl-CoA units with a 
starter (S)-2-methylbutyryl-CoA, which is derived from L-isoleucine, in primary fatty 
acid biosynthesis. Hafner et al. reported that the branched-chain 2-oxo acid 
decarboxylase is specific to the (S)-isomer of 3-methyl-2-oxopentanoic acid for the 
synthesis of anteiso-type fatty acids and avermectins in S. avermitilis.[30]  
   The minimum concentrations of SRB1 (1=1a) and SRB2 (2=2a) to induce antibiotic 
production in S. rochei were 42 nM and 40 nM, respectively. These values were lower 
than that of SCB1 (128-256 nM) for actinorhodin and undecylprodigiosin production in 
S. coelicolor[31] and higher than those of A-factor (around 1 nM) for streptomycin in S. 
griseus[6] and virginia butanolides (around 3 nM) for virginiamycin in S. virginiae.[32] 
The synthetic 1’S-isomers 1b and 2b exhibited remarkably weaker activity than the 
1’R-isomers 1a and 2a, indicating that the stereochemistry of C-1’ is crucial for 
inducing activity. Our preliminary experiments demonstrated that 2,3-dihydro-SRB1, 
 12 
which was prepared from 1a via catalytic hydrogenation, showed no ability to induce 
antibiotic production in S. rochei at a concentration of 33.5 µM, indicating the 
importance of the C2-C3 double bond for activity. The function of the C-4 hemiacetal 
hydroxyl and the C-6’ ketone groups together with the chain length should also be 
studied in due course. It was reported that higher concentrations of SCB1 (>1,000 nM) 
inhibited antibiotic production in S. coelicolor, but did not affect growth and 
morphological development.[31] A similar effect on antibiotic production was also 
observed for virginiae butanolides in S. virginiae.[33] In contrast, the inhibitory effect on 
the antibiotic production and morphological differentiation was not observed for SRBs 
in S. rochei even at the concentration of 6,700 nM. We previously observed a negative 
effect of srrX on spore formation on the basis of gene inactivation experiments.[18] 
However, the present work clearly indicates that SRBs themselves have no inhibitory 
effect on spore formation. Thus, it may be possible that the SrrX protein has a 
regulatory function in morphological differentiation. 
   Concerning the biosynthesis of SRB1 and SRB2, we speculated that srrX encodes a 
key enzyme like afsA in S. griseus based on the following evidences. (1) SRB1 and 
SRB2 resemble possible intermediates of the γ-butyrolactone signaling molecules. (2) 
The culture extract of the srrX mutant has no inducing activity of antibiotic production 
in S. rochei. (3) No other positive signals were detected in S. rochei DNA when srrX 
was used as a probe for hybridization. Consistent with these speculation, several 
possible genes for SRB biosynthesis were found around srrX (orf85) on pSLA2-L; an 
NAD-dependent dehydrogenase gene srrG (orf81), a phosphatase gene srrP (orf83), a 
P450 hydroxylase gene srrO (orf84), and a thioesterase gene srrH (orf86). By analogy 
to the biosynthesis of A-factor[7] and virginia butanolides,[34] SrrX may be responsible 
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for the coupling between a C3 unit and a β-keto acid of C12 or C13 derived from fatty 
acid biosynthesis, followed by spontaneous intramolecular aldol condensation to form a 
butenolide skeleton. Then, the butenolide intermediate is further modified by 
biosynthetic enzymes including SrrG to synthesize SRBs. The SrrG protein is 
homologous to BarS1, which is involved in the reduction of the C-1’ ketone group to 
produce virginia butanolides in S. virginiae.[35] Our preliminary data showed that a 
mutation of srrG abolished lankacidin and lankamycin production in S. rochei 
(unpublished result). Comprehensive analyses of SRB biosynthetic pathway by gene 
inactivation and feeding experiments are in progress in our laboratory. 
 
 
Experimental Section 
 
Strains and culture conditions: S. rochei wild-type strain 7434AN4 and strain 51252 
that carries only pSLA2-L were described previously.[13,15] Strain KA61, a disruptant of 
the SARP-family transcriptional activator gene srrY, was used as an SRB producer.[20] 
Strain KA20, a double mutant of srrX and the transcriptional repressor gene srrB, was 
used as an SRB indicator strain.[18] YM medium (0.4% yeast extract, 1.0% malt extract, 
and 0.4% D-glucose, pH 7.3) was used for SRB synthesis and bioassay.  
Spectroscopic instruments: NMR spectra were recorded on a JEOL LA-500 
spectrometer equipped with a field gradient accessory. CDCl3 (99.8 atom% enriched; 
Acros) was used as a solvent. Chemical shifts were recorded as a δ value based on a 
resident solvent signal (δC 77.0), or an internal standard signal of tetramethylsilane (δH 
0). Electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI) 
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mass spectra were measured by a LTQ Orbitrap XL mass spectrometer (Thermo Fisher 
Scientific, USA). Optical rotations were measured with a JASCO DIP-370 polarimeter. 
IR spectra were recorded on a JASCO FT/IR-5300 spectrometer. UV spectra were 
obtained on an Ultrospec 3300pro UV/visible spectrophotometer (Amersham 
Biosciences). 
Isolation of SRB molecules: An inoculum of strain KA61 was grown using a two-stage 
seed culture system. The first-stage seed culture (50 mL) was used as an inoculum to 4 
liter medium, which was grown at 28°C and 90 rpm for 28 h.  The resulting 
second-stage seed culture was inoculated into 160 liter of YM medium, which was 
cultivated at 28°C and 110 rpm with an airflow rate of 0.5 vvm (air volume/liquid 
volume per minute) for 43 h. The culture supernatant was passed through a column of 
Amberlite® XAD16 resin (Sigma) (5 kg) at a flow rate of 10 Lh–1 to absorb hydrophobic 
compounds including SRBs. The resin was extracted with equal volume of EtOAc three 
times. The combined organic phase was dried (Na2SO4), filtered, and concentrated to 
dryness. The resulting residue (18 g) was purified by silica gel chromatography with 
hexane-EtOAc (1:1 to 1:2, v/v). Each fraction was subjected to bioassay using strain 
KA20 as a test organism (see below). Active fractions were collected and purified by 
Sephadex LH-20 (GE Healthcare) with methanol, which was further purified by a series 
of silica gel column chromatography with three different solvent systems of 
CHCl3-MeOH (50:1-30:1, v/v), toluene-EtOAc (2:1-1:1, v/v), and hexane-EtOAc 
(2:1-1:1, v/v). The purified sample was analyzed by ESI-MS and NMR (Figure 1). The 
1H and 13C NMR assignments were supported by 1H-1H COSY, HMQC, and HMBC 
experiments (Supporting information). 
Compound 1 (SRB1): high resolution ESI-MS; observed m/z 321.1671 [M+Na]+ (calcd 
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for C16H26O5Na, 321.1673).  
Compound 2 (SRB2): high resolution ESI-MS; observed m/z 307.1513 [M+Na]+ (calcd 
for C15H24O5Na, 307.1516).  
Optical rotation of natural SRBs: [α]D22 = +17.5 (c = 0.012, CHCl3). 
SRB assay: The srrX-srrB double mutant KA20 was used as a highly sensitive SRB 
indicator, because this strain produces two antibiotics like the srrB mutant when SRBs 
are added. A seed culture of strain KA20 (100 µL) supplemented with an aliquot of 
fraction (10 µL) was grown in YM liquid medium (5 mL) at 28°C for 24 h. Antibiotic 
production was analyzed by high performance liquid chromatography (HPLC) and thin 
layer chromatography (TLC) as follows. The crude extract was applied on a 
COSMOSIL 5C18-MS-II column (4.6 x 250 mm, Nakarai Tesque, Japan) and eluted 
with a mixture of acetonitrile-10 mM sodium phosphate buffer (pH 8.2) (3:7, v/v) at a 
flow rate of 1.0 mLmin–1. The eluate was monitored at 230 nm with a JASCO MD-2010 
multiwavelength photodiode array detector. Lankacidin C and lankacidinol A were 
detected at 8.5 min and 16.9 min, respectively. TLC was developed with a mixture of 
CHCl3-methanol (15:1, v/v) and baked after spraying with anisaldehyde-H2SO4. 
1-(Benzyloxy)-6-hexanal (4): A mixture of 1-(benzyloxy)-6-hexanol (3)[23] (8.00 g, 
38.4 mmol), pyridinium chlorochromate (PCC) (12.8 g, 59.5 mmol), and sodium acetate 
(1.40 g, 17.1 mmol) in CH2Cl2 (200 mL) was stirred at room temperature for 1.5 h. The 
mixture was diluted with ether (300 mL), and filtered through a pad of Celite. The 
filtrate and washings were concentrated in vacuo. The residue was purified over silica 
gel with hexane-EtOAc (7:1, v/v) to give 4 (6.45 g, 81%) as a colorless oil. 
1H NMR (CDCl3): δ = 1.40-1.45 (2H, m, H-3), 1.61-1.68 (4H, m, H-2 and H-4), 
2.35 (1H, t, J = 7.4 Hz, H-5a), 2.43 (1H, dt, J = 1.8 and 7.4 Hz, H-5b), 3.47 (2H, t, J = 
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6.4 Hz, H-1), 4.50 (2H, s, Ph-CH2), 7.25-7.37 (5H, m, Ph-CH2), 9.75 (1H, t, J = 1.8 Hz, 
H-6); 13C NMR (CDCl3): δ = 21.9 (C-3), 24.5 (C-4), 29.4 (C-2), 43.7 (C-5), 70.0 (C-1), 
202.7 (C-6), benzyl resonances: 72.9 (Ph-CH2), 127.5, 127.6, 128.4, 138.6; High 
resolution ESI-MS: observed m/z 229.1199 [M+Na]+ (calcd for C13H18O2Na, 
229.1199) ; IR (neat): ν~ = 2938, 2861, 1725, 1454, 1364, 1101, 739, 698 cm–1. 
1-(Benzyloxy)-8-methylnonan-6-ol (5): To a suspension of magnesium (2.00 g, 82.3 
mmol) and iodine (160 mg) in THF (40 mL) was added 1-bromo-2-methylpropane (9.00 
mL, 83.4 mmol) at 0°C, and the mixture was stirred at 0°C for 2 h. A solution of 
aldehyde 4 (2.82 g, 13.7 mmol) in THF (10 mL) was added dropwise to the mixture at 
0°C, and the mixture was stirred at room temperature for 2.5 h. Saturated aqueous 
NH4Cl (50 mL) was added, and the mixture was extracted with EtOAc twice. The 
combined organic phases were washed with brine, dried (Na2SO4), filtered, and 
concentrated to dryness. The residue was purified over silica gel with hexane-EtOAc 
(7:1-5:1, v/v) to give 5 (2.93 g, 81%) as a colorless oil. 
Diastereomer mixture: 1H NMR (CDCl3): δ = 0.91 (6H, t, J = 7.0 Hz, H-9 and H-9’), 
1.22 (1H, m, H-7a), 1.32-1.46 (7H, m, H-3,4,5,7b), 1.63 (2H, t, J = 7.0 Hz, H-2), 1.76 
(1H, m, H-8), 3.47 (2H, t, J = 6.7 Hz, H-1), 3.66 (1H, br, H-6), 4.50 (2H, s, Ph-CH2), 
7.26-7.34 (5H, m, Ph-CH2); 13C NMR (CDCl3): δ = 22.0 (C-9), 23.5 (C-9’), 24.6 (C-8), 
25.4 (C-4), 26.3 (C-3), 29.7 (C-2), 38.0 (C-5), 46.8 (C-7), 69.9 (C-6), 70.3 (C-1), benzyl 
resonances: 72.8 (Ph-CH2), 127.5, 127.6, 128.3, 138.6; High resolution ESI-MS: 
observed m/z 287.1981 [M+Na]+ (calcd for C17H28O2Na, 287.1982); IR (neat): ν~ = 
3397, 2932, 2863, 1454, 1366, 1101, 735, 698 cm–1. 
1-(Benzyloxy)-8-methylnonan-6-one (6): A mixture of alcohol 5 (2.90 g, 11.0 mmol), 
PCC (3.75 g, 17.4 mmol), and sodium acetate (290 mg, 3.54 mmol) in CH2Cl2 (60 mL) 
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was stirred at room temperature for 2 h. The mixture was diluted with ether (100 mL), 
and filtered through a pad of Celite. The filtrate and washings were concentrated in 
vacuo. The residue was purified over silica gel with hexane-EtOAc (10:1, v/v) to give 6 
(2.37 g, 82%) as a colorless oil. 
1H NMR (CDCl3): δ = 0.90 (6H, d, J = 6.4 Hz, H-9 and H-9’), 1.34-1.40 (2H, m, 
H-3), 1.55-1.66 (4H, m, H-2 and H-4), 2.13 (1H, m, H-8), 2.26 (2H, d, J = 7.0 Hz, H-7), 
2.37 (2H, t, J = 7.4 Hz, H-5), 3.46 (2H, t, J = 6.4 Hz, H-1), 4.49 (2H, s, Ph-CH2), 
7.25-7.35 (5H, m, Ph-CH2); 13C NMR (CDCl3): δ = 22.6 (C-9 and C-9’), 23.5 (C-4), 
24.6 (C-8), 25.8 (C-3), 29.5 (C-2), 43.2 (C-5), 51.8 (C-7), 70.1 (C-1), 211.0 (C-6), 
benzyl resonances: 72.9 (Ph-CH2), 127.5, 127.6, 128.3, 138.6; High resolution ESI-MS: 
observed m/z 285.1822 [M+Na]+ (calcd for C17H26O2Na, 285.1825); IR (neat): ν~ = 
2936, 2866, 1711, 1454, 1366, 1103, 737, 698 cm–1. 
5-(2’-Isobutyl-1’,3’-dioxolan-2’-yl)pentanal (7): To a solution of ketone 6 (2.30 g, 
8.77 mmol) and ethylenedioxybis(trimethylsilane) (4.20 mL, 17.1 mmol) in CH2Cl2 (80 
mL) was added trimethylsilyl trifluoromethanesulfonate (TMSOTf) (300 µL, 1.66 
mmol) at –78°C, and the mixture was stirred at –78°C for 1 h and at room temperature 
for 7 h. Pyridine (1 mL) and water (10 mL) were added at 0°C, and the mixture was 
extracted with CH2Cl2 twice. The combined organic phases were washed with brine, 
dried (Na2SO4), filtered, and concentrated to dryness. The residue was purified over 
silica gel with hexane-EtOAc (20:1, v/v) to give the corresponding dioxolane derivative 
(2.43 g, 90%) as a colorless oil. A mixture of the dioxolane derivative (2.40 g, 7.83 
mmol) and 10% Pd-C (750 mg) in EtOAc (60 mL) was stirred at room temperature for 
24 h under hydrogen atmosphere. The mixture was passed through a pad of Celite. The 
filtrate and washings were concentrated in vacuo. The residue was purified over silica 
 18 
gel with hexane-EtOAc (4:1-2:1, v/v) to give the deprotected alcohol (1.61 g, 95%) as a 
colorless oil. A mixture of this alcohol (1.61 g, 7.44 mmol), PCC (3.40 g, 15.8 mmol), 
and sodium acetate (280 mg, 3.41 mmol) in CH2Cl2 (60 mL) was stirred at room 
temperature for 4 h. The mixture was diluted with ether (50 mL), and filtered through a 
pad of Celite. The filtrate and washings were concentrated in vacuo. The residue was 
purified over silica gel with hexane-EtOAc (5:1, v/v) to give 7 (1.20 g, 75%) as a 
colorless oil. Overall yield; 64% (three steps). 
1H NMR (CDCl3): δ = 0.94 (6H, d, J = 6.7 Hz, CH3x2), 1.37-1.44 (2H, m, H-4), 
1.51 (2H, m, iPr-CH2), 1.60-1.67 (4H, m, H-3 and H-5), 1.75 (1H, m, Me2CH), 2.43 
(2H, m, H-2), 3.91 (4H, m, (CH2O-)2), 9.76 (1H, t, J = 1.9 Hz, H-1); 13C NMR 
(CDCl3): δ = 22.3 (C-3), 23.4 (C-4), 24.0 (Me2CH), 24.1 (Me2CH), 37.1 (C-5), 43.9 
(C-2), 45.2 (iPr-CH2), 64.6 ((CH2O-)2), 111.7 (C-2’), 202.6 (C-1); High resolution 
APCI-MS: observed m/z 215.1642 [M+H]+ (calcd for C12H23O3, 215.1642); IR (neat): 
ν~ = 2953, 2872, 1711, 1466, 1366, 1090, 949 cm–1. 
(1’R)-2-(1'-hydroxyl-5'-(2''-isobutyl-1'',3''-dioxolan-2''-yl)pentyl)-3-methyl-4-(L-m
enthyloxy)but-2-en-1,4-olide (9a) and 
(1’S)-2-(1'-hydroxyl-5'-(2''-isobutyl-1'',3''-dioxolan-2''-yl)pentyl)-3-methyl-4-(L-me
nthyloxy)but-2-en-1,4-olide (9b): A solution of n-butyl lithium (2.80 mL, 1.65 M in 
hexane, 4.62 mmol) was added dropwise to a solution of diisopropylamine (640 µL, 
4.55 mmol) in THF (10 mL) at 0°C. After 30 min of stirring, hexamethylphosphoric 
triamide (HMPA) (4 mL) was added dropwise to the mixture at 0°C. A solution of 
readily available 3-methyl-4-(L-menthyloxy)but-2-en-1,4-olide (8) (1.15 g, 4.55 
mmol)[24,25] in THF (12 mL) was added dropwise at –78°C, and the mixture was further 
stirred at the same temperature for 30 min. Then a solution of aldehyde 7 (1.05 g, 4.90 
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mmol) in THF (10 mL) was added dropwise at –78°C within 10 min, and the mixture 
was further stirred at the same temperature for 1.5 h. Saturated aqueous NH4Cl (10 mL) 
was added to the mixture, and the mixture was extracted with CH2Cl2 twice. The 
combined organic phases were washed with brine, dried (Na2SO4), filtered, and 
concentrated to dryness. The residue was purified by silica gel chromatography with 
hexane-EtOAc (4:1, v/v) to give a 2:1 mixture of 9a and 9b (660 mg, 31%) as a 
colorless oil, which were further separated by repeated runs of flash chromatography. 
The absolute configuration at C-1’ was established by the modified Mosher method.[27] 
The differences in chemical shifts (∆δ) were obtained by subtracting the δ value of 
(R)-MTPA ester from that of (S)-MTPA ester (δS – δR).  
Compound 9a: [α]D27 = –58.8 (c = 1.10, CHCl3); 1H NMR (CDCl3): δ = 0.91 (3H, 
d, J = 6.7 Hz, Me2CH), 0.93 (3H, d, J = 6.8 Hz, Me2CH), 1.28-1.42 (2H, m, C-3’), 1.50 
(2H, d, J = 6.1 Hz, iPr-CH2), 1.59-1.63 (5H, m, H-2’a,4’,5’), 1.75 (1H, m, Me2CH), 
1.83 (1H, m, H-2’b), 1.97 (3H, s, H-5), 2.86 (1H, br, C1’-OH), 3.91 (4H, m, (CH2O-)2), 
4.46 (1H, t, J = 6.7 Hz, H-1’), 5.69 (1H, s, H-4), menthyl resonances: 0.81 (3H, d, J = 
6.8 Hz), 0.86 (1H, m), 0.88 (3H, d, J = 7.1 Hz), 0.96 (3H, d, J = 6.4 Hz), 1.02 (2H, m), 
1.22-1.27 (1H, m), 1.28-1.42 (1H, m), 1.64-1.70 (2H, m), 2.08-2.14 (2H, m), 3.62 (1H, 
dt, J = 4.3 and 11 Hz); 13C NMR (CDCl3): δ = 11.5 (C-5), 23.5 (C-4’), 24.0 (Me2CH), 
24.1 (Me2CH), 25.7 (C-3’), 36.6 (C-2’), 37.2 (C-5’), 45.2 (iPr-CH2), 64.6 ((CH2O-)2), 
66.9 (C-1’), 100.9 (C-4), 111.9 (C-2’’), 130.6 (C-2), 155.4 (C-3), 171.4 (C-1), menthyl 
resonances: 15.9, 20.8, 22.2, 23.2, 25.3, 31.4, 34.2, 40.5, 47.7, 79.6; High resolution 
ESI-MS: observed m/z 489.3182 [M+Na]+ (calcd for C27H46O6Na, 489.3187); IR 
(neat): ν~ = 2953, 2870, 1759, 1458, 1370, 1331, 1094, 947, 756 cm–1. 
Compound 9b: [α]D28 = –99.5 (c = 0.760, CHCl3); 1H NMR (CDCl3): δ = 0.91 (3H, 
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d, J = 6.4 Hz, Me2CH), 0.93 (3H, d, J = 6.8 Hz, Me2CH), 1.28-1.42 (2H, m, C-3’), 1.50 
(2H, d, J = 6.1 Hz, iPr-CH2), 1.59-1.72 (5H, m, H-2’a,4’,5’), 1.75 (1H, m, Me2CH), 
1.83 (1H, m, H-2’b), 1.99 (3H, s, H-5), 3.91 (4H, m, (CH2O-)2), 4.48 (1H, t, J = 7.3 Hz, 
H-1’), 5.71 (1H, s, H-4), menthyl resonances: 0.80 (3H, d, J = 7.0 Hz), 0.86 (1H, m), 
0.87 (3H, d, J = 7.1 Hz), 0.96 (3H, d, J = 6.7 Hz), 1.05 (2H, m), 1.22-1.27 (1H, m), 
1.28-1.42 (1H, m), 1.59-1.72 (2H, m), 2.10-2.15 (2H, m), 3.62 (1H, dt, J = 4.3 and 11 
Hz); 13C NMR (CDCl3): δ = 11.5 (C-5), 23.5 (C-4’), 24.0 (Me2CH), 24.1 (Me2CH), 
25.7 (C-3’), 36.4 (C-2’), 37.2 (C-5’), 45.1 (iPr-CH2), 64.5 ((CH2O-)2), 66.7 (C-1’), 
100.7 (C-4), 111.8 (C-2’’), 130.7 (C-2), 155.4 (C-3), 171.4 (C-1), menthyl resonances: 
15.7, 20.8, 22.2, 23.1, 25.1, 31.4, 34.2, 40.4, 47.7, 79.5; High resolution ESI-MS: 
observed m/z 489.3184 [M+Na]+ (calcd for C27H46O6Na, 489.3187); IR (neat): ν~ = 
2953, 2870, 1759, 1456, 1370, 1333, 1096, 947 cm–1. 
SRB1a (1a): To a solution of 9a (82 mg, 0.18 µmol) in CH2Cl2 (3.0 mL) was added 
10% BBr3 solution in CH2Cl2 (400 µL, 420 µmol) at –78°C, and the mixture was 
stirred at –78°C for 1.5 h. Saturated aqueous NaHCO3 (2 mL) was carefully added, and 
the mixture was extracted with EtOAc twice. The combined organic phases were 
washed with brine, dried (Na2SO4), filtered, and concentrated to dryness. The residue 
was purified by silica gel chromatography with hexane-EtOAc (1:1, v/v) to give SRB1a 
(1a) (26 mg, 52%) as a colorless oil. 
   Mixture of C-4 epimers: [α]D24 = +18.4 (c = 0.860, CHCl3); 1H NMR and 13C NMR 
assignments were listed in Table 1; High resolution ESI-MS: observed m/z 307.1519 
[M+Na]+ (calcd for C15H24O5Na, 307.1516); UV/Vis (MeOH): λmax (log ε) = 210 nm 
(3.98); IR (neat): ν~ = 3389, 2957, 2872, 1752, 1705, 1464, 1370, 1335, 1088, 955, 758 
cm–1. 
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SRB1b (1b): The compound 9b (23 mg, 50 µmol) was treated in the same manner as 
described for the preparation of 1a to give SRB1b (1b) (8.9 mg, 63%) as a colorless oil. 
   Mixture of C-4 epimers: [α]D25 = –9.32 (c = 0.400, CHCl3); 1H NMR (CDCl3): δ = 
0.89 (3H, d, J = 6.4 Hz, H-9’ or H-9’’), 0.90 (3H, d, J = 6.4 Hz, H-9’’ or H-9’), 1.25 (1H, 
m, H-3’a), 1.36 (1H, m, H-3’b), 1.53 (2H, m, H-4’), 1.69-1.81 (2H, m, H-2’), 2.08/2.09 
(3H, s, H-5), 2.09 (1H, m, H-8’), 2.26 (2H, d, J = 7.1 Hz, H-7’), 2.40 (2H, dt, J = 2.2 
and 7.1 Hz, H-5’), 4.46 (1H, m, H-1’), 5.85 (1H, brs, H-4); 13C NMR (CDCl3): δ = 
11.5/11.6 (C-5), 22.5/22.6 (C-9’ and C-9’’), 22.9/23.2 (C-4’), 24.5/24.7 (C-8’), 
24.7/24.8 (C-3’), 35.6/35.7 (C-2’), 42.6/42.8 (C-5’), 51.9/52.0 (C-7’), 66.4/66.6 (C-1’), 
98.5/98.8 (C-4), 129.9/130.3 (C-2), 157.1/157.2 (C-3), 171.1/171.2 (C-1), 211.4/212.6 
(C-6’); High resolution ESI-MS: observed m/z 307.1515 [M+Na]+ (calcd for 
C15H24O5Na, 307.1516); UV/Vis (MeOH): λmax (log ε) = 210 nm (4.02); IR (neat): ν~ = 
3389, 2957, 2872, 1752, 1705, 1464, 1370, 1335, 1088, 955, 758 cm–1. 
(8S)-1-(Benzyloxy)-8-methyldecan-6-ol (10): To a suspension of magnesium (2.05 g, 
84.3 mmol) and iodine (135 mg) in THF (35 mL) was added 
(S)-(+)-1-chloro-2-methylbutane (9.00 mL, 75.1 mmol) at room temperature, and the 
mixture was stirred at 70°C for 2 h. A solution of aldehyde 4 (2.78 g, 13.5 mmol) in 
THF (10 mL) was added dropwise to the mixture at 0°C, and the mixture was stirred at 
room temperature for 1 h. Saturated aqueous NH4Cl (30 mL) was added, and the 
mixture was extracted with EtOAc twice. The combined organic phases were washed 
with brine, dried (Na2SO4), filtered, and concentrated to dryness. The residue was 
purified over silica gel with hexane-EtOAc (7:1-5:1, v/v) to give 10 (2.55 g, 68%) as a 
colorless oil. 
Diastereomer mixture: 1H NMR (CDCl3): δ = 0.85-0.92 (6H, m, H-9’ and H-10), 
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1.11 (1H, m, H-9a), 1.25-1.50 (10H, m, H-3,4,5,7,8,9b), 1.63 (2H, t, J = 6.7 Hz, H-2), 
3.47 (2H, t, J = 6.7 Hz, H-1), 3.68 (1H, m, H-6), 4.50 (2H, s, Ph-CH2), 7.25-7.34 (5H, 
m, Ph-CH2); 13C NMR (CDCl3): δ = 11.1/11.3 (C-10), 18.8/19.8 (C-9’), 25.3/25.5 (C-4), 
26.3 (C-3), 29.0/30.4 (C-9), 29.7 (C-2), 30.8/31.1 (C-8), 37.7/38.3 (C-5), 44.6/44.8 
(C-7), 69.6/69.9 (C-6), 70.3 (C-1), benzyl resonances: 72.8 (Ph-CH2), 127.5, 127.6, 
128.3, 138.7; High resolution ESI-MS: observed m/z 301.2142 [M+Na]+ (calcd for 
C18H30O2Na, 301.2138); IR (neat): ν~ = 3397, 2930, 2857, 1454, 1101, 735, 698 cm–1. 
(8S)-1-(Benzyloxy)-8-methyldecan-6-one (11): The alcohol 10 (2.50 g, 8.98 mmol) 
was treated in the same manner as described for the preparation of 6 to give 11 (1.53 g, 
62%) as a colorless oil. 
 [α]D26 = +2.40 (c = 0.500, CHCl3); 1H NMR (CDCl3): δ = 0.86 (3H, d, J = 6.7 Hz, 
H-9’), 0.87 (3H, t, J = 7.4 Hz, H-10), 1.18 (1H, m, H-9a), 1.30 (1H, m, H-9b), 1.37 (2H, 
m, H-3), 1.55-1.65 (4H, m, H-2 and H-4), 1.91 (1H, m, H-8), 2.18 (1H, dd, J = 8.0 and 
16 Hz, H-7a), 2.35-2.42 (3H, m, H-5 and H-7b), 3.46 (2H, t, J = 6.7 Hz, H-1), 4.49 (2H, 
s, Ph-CH2), 7.25-7.35 (5H, m, Ph-CH2); 13C NMR (CDCl3): δ = 11.3 (C-10), 19.4 
(C-9’), 23.5 (C-4), 25.8 (C-3), 29.5 (C-9), 29.6 (C-2), 30.8 (C-8), 43.2 (C-5), 49.9 (C-7), 
70.2 (C-1), 211.2 (C-6), benzyl resonances: 72.9 (Ph-CH2), 127.5, 127.6, 128.3, 138.6; 
High resolution ESI-MS: observed m/z 299.1983 [M+Na]+ (calcd for C18H28O2Na, 
299.1982); IR (neat): ν~ = 2936, 2861, 1713, 1456, 1366, 1103, 737, 698 cm–1. 
5-(2’-((2”S)-2”-methylbutyl)-1’,3’-dioxolan-2’-yl)pentanal (12): The compound 11 
(1.50 g, 5.43 mmol) was treated in the same manner as described for the preparation of 
7 to give 12 (720 mg, 58% in three steps) as a colorless oil. 
 [α]D27 = +5.92 (c = 1.09, CHCl3); 1H NMR (CDCl3): δ = 0.86 (3H, t, J = 7.4 Hz, 
MeCH2), 0.93 (3H, d, J = 6.4 Hz, MeCH), 1.17 (1H, m, MeCH2a), 1.36-1.44 (4H, m, 
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H-4 and MeCHCH2), 1.51 (1H, m, MeCH), 1.60-1.67 (5H, m, H-3, 5, and MeCH2b), 
2.44 (2H, dt, J = 1.9 and 7.4 Hz, H-2), 3.91 (4H, m, (CH2O-)2), 9.76 (1H, t, J = 1.9 Hz, 
H-1); 13C NMR (CDCl3): δ = 11.3 (MeCH2), 20.5 (MeCH), 22.3 (C-3), 23.4 (C-4), 30.4 
(MeCH), 30.6 (MeCH2), 37.1 (C-5), 43.1 (MeCHCH2), 43.9 (C-2), 64.6/64.7 
((CH2O-)2), 111.9 (C-2’), 202.6 (C-1); High resolution APCI-MS: observed m/z 
229.1796 [M+H]+ (calcd for C13H25O3, 229.1798); IR (neat): ν~ = 2957, 2876, 1725, 
1462, 1377, 1138, 1082, 949 cm–1. 
(1’R)-2-(1’-hydroxyl-5’-(2”-((2”’S)-2’-methylbutyl-1”,3”-dioxolan-2”-yl)pentyl)-3-
methyl-4-(L-menthyloxy)but-2-en-1,4-olide (13a) and 
(1’S)-2-(1’-hydroxyl-5’-(2”-((2”’S)-2’-methylbutyl-1”,3”-dioxolan-2”-yl)pentyl)-3-
methyl-4-(L-menthyloxy)but-2-en-1,4-olide (13b): The compound 12 (670 mg, 2.93 
mmol) was treated in the same manner as described for the preparation of 9 to give a 2:1 
mixture of 13a and 13b (656 mg, 54%) as a colorless oil, which was also further 
separated by flash chromatography. 
   Compound 13a: [α]D23 = –72.4 (c = 1.27, CHCl3); 1H NMR (CDCl3): δ = 0.86 (3H, 
t, J = 7.3 Hz, MeCH2), 0.93 (3H, d, J = 6.8 Hz, MeCH), 1.14-1.20 (1H, m, MeCH2a), 
1.31-1.42 (6H, m, H-3’, 4’, MeCH2b, and MeCHCH2a), 1.50 (1H, m, MeCH), 
1.59-1.63 (4H, m, H-2’a, 5’, and MeCHCH2b), 1.84 (1H, m, H-2’b), 1.97 (3H, s, H-5), 
2.85 (1H, d, J = 9.2 Hz, C1’-OH), 3.91 (4H, m, (CH2O-)2), 4.46 (1H, q, J = 8.2 Hz, 
H-1’), 5.69 (1H, s, H-4), menthyl resonances: 0.81 (3H, d, J = 7.1 Hz), 0.86 (1H, m), 
0.87 (3H, d, J = 7.3 Hz), 0.96 (3H, d, J = 6.7 Hz), 1.10 (2H, m), 1.25 (1H, m), 1.31-1.42 
(1H, m), 1.64-1.71 (2H, m), 2.10 (2H, m), 3.62 (1H, dt, J = 4.3 and 11 Hz); 13C NMR 
(CDCl3): δ = 11.3 (MeCH2), 11.5 (C-5), 20.4 (MeCH), 23.5 (C-4’), 25.7 (C-3’), 30.3 
(MeCH), 30.6 (MeCH2), 36.6 (C-2’), 37.2 (C-5’), 43.1 (MeCHCH2), 64.5/64.7 
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((CH2O-)2), 66.9 (C-1’), 100.9 (C-4), 112.0 (C-2’’), 130.6 (C-2), 155.4 (C-3), 171.4 
(C-1), menthyl resonances: 15.9, 20.8, 22.2, 23.2, 25.4, 31.5, 34.2, 40.5, 47.7, 79.6; 
High resolution ESI-MS: observed m/z 503.3339 [M+Na]+ (calcd for C28H48O6Na, 
503.3343); IR (neat): ν~ = 2955, 2926, 1755, 1456, 1372, 1331, 1096, 949, 758 cm–1. 
 Compound 13b: [α]D22 = –74.4 (c = 0.860, CHCl3). 1H NMR (CDCl3): δ = 0.86 
(3H, t, J = 7.3 Hz, MeCH2), 0.93 (3H, d, J = 6.4 Hz, MeCH), 1.14-1.20 (1H, m, 
MeCH2a), 1.31-1.42 (6H, m, H-3’, 4’, MeCH2b, and MeCHCH2a), 1.50 (1H, m, 
MeCH), 1.59-1.71 (4H, m, H-2’a, 5’, and MeCHCH2b), 1.82 (1H, m, H-2’b), 1.98 (3H, 
s, H-5), 2.39 (1H, m, C1’-OH), 3.91 (4H, m, (CH2O-)2), 4.47 (1H, t, J = 7.3 Hz, H-1’), 
5.71 (1H, s, H-4), menthyl resonances: 0.80 (3H, d, J = 6.7 Hz), 0.86 (1H, m), 0.87 (3H, 
d, J = 7.1 Hz), 0.96 (3H, d, J = 6.7 Hz), 1.10 (2H, m), 1.26 (1H, m), 1.31-1.42 (1H, m), 
1.59-1.71 (2H, m), 2.12 (2H, m), 3.62 (1H, dt, J = 4.3 and 11 Hz); 13C NMR (CDCl3): δ 
=11.3 (MeCH2), 11.5 (C-5), 20.4 (MeCH), 23.5 (C-4’), 25.7 (C-3’), 30.3 (MeCH), 30.6 
(MeCH2), 36.4 (C-2’), 37.2 (C-5’), 43.1 (MeCHCH2), 64.5/64.6 ((CH2O-)2), 66.8 
(C-1’), 100.7 (C-4), 112.0 (C-2’’), 130.7 (C-2), 155.4 (C-3), 171.4 (C-1), menthyl 
resonances: 15.7, 20.8, 22.2, 23.1, 25.2, 31.4, 34.2, 40.4, 47.7, 79.5; High resolution 
ESI-MS: observed m/z 503.3341 [M+Na]+ (calcd for C28H48O6Na, 503.3343); IR 
(neat): ν~ = 2955, 2872, 1761, 1456, 1372, 1331, 1096, 949 cm–1. 
SRB2a (2a): The compound 13a (20 mg, 42 µmol) was treated in the same manner as 
described for the preparation of 1a to give SRB2a (2a) (8.4 mg, 70%) as a colorless oil. 
   Mixture of C-4 epimers: [α]D22 = +22.4 (c = 0.800, CHCl3); 1H NMR and 13C NMR 
assignments were listed in Table 1; High resolution ESI-MS: observed m/z 321.1676 
[M+Na]+ (calcd for C16H26O5Na, 321.1673); UV/Vis (MeOH): λmax (log ε) = 210 nm 
(4.06); IR (neat): ν~ = 3397, 2959, 2932, 2876, 1750, 1705, 1460, 1381, 1337, 1090, 957, 
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756 cm–1. 
SRB2b (2b): The compound 13b (20 mg, 42 µmol) was treated in the same manner as 
described for the preparation of 1a to give SRB2b (2b) (6.8 mg, 55%) as a colorless oil. 
   Mixture of C-4 epimers: [α]D24 = –5.71 (c = 0.700, CHCl3); 1H NMR (CDCl3): δ = 
0.86 (3H, d, J = 7.0 Hz, H-9’’), 0.87 (3H, t, J = 6.7 Hz, H-10’), 1.15-1.20 (1H, m, 
H-9’a), 1.21-1.32 (2H, m, H-3’), 1.30-1.40 (1H, m, H-9’b), 1.51-1.59 (2H, m, H-4’), 
1.65-1.80 (1H, m, H-2’a), 1.81-1.93 (2H, m, H-2’b and H-8’), 2.08/2.09 (3H, s, H-5), 
2.17 (1H, d, J = 7.9 and 8.0 Hz, H-7’a), 2.35-2.42 (3H, m, H-5’ and H-7’b), 3.03 (1H, br, 
C1’-OH), 4.49 (1H, m, H-1’), 5.85 (1H, brs, H-4); 13C NMR (CDCl3): δ = 11.3/11.3 
(C-10’), 11.5/11.6 (C-5), 19.3/19.4 (C-9’’), 23.0/23.2 (C-4’), 24.6/24.8 (C-3’), 29.5/29.5 
(C-9’), 30.9 (C-8’), 35.6 (C-2’), 42.7/42.9 (C-5’), 50.0/50.1 (C-7’), 66.4/66.5 (C-1’), 
98.7/98.9 (C-4), 129.9/130.1 (C-2), 157.4/157.5 (C-3), 171.3/171.4 (C-1), 211.7/212.8 
(C-6’); High resolution ESI-MS: observed m/z 321.1676 [M+Na]+ (calcd for 
C16H26O5Na, 321.1673); UV/Vis (MeOH): λmax (log ε) = 210 nm (4.03); IR (neat): ν~ = 
3397, 2959, 2932, 2876, 1750, 1705, 1460, 1381, 1337, 1090, 957, 756 cm–1. 
Chiral HPLC analysis: Natural SRB1 and SRB2 (1 and 2), synthetic 1a, 1b, 2a, and 
2b were dissolved in acetonitrile (30 µgmL–1), and an aliquot of each sample (10 µL) 
was analyzed by HPLC using a Chiral MB-S column (macroporous silica gel coated 
with optically active N-substituted polymaleimides, 4.6 x 250 mm, Tokyo Chemical 
Industry, Co., Ltd., Japan) with 10% aqueous acetonitrile containing 0.1% 
trifluoroacetic acid as solvent at a flow rate of 1.0 mLmin–1, and with detection at 210 
nm. Natural SRB1 (1) and SRB2 (2) were eluted at 9.1 and 17.3 min. Synthetic 1a, 1b, 
2a, and 2b were eluted at 9.1, 8.7, 17.3, and 16.6 min, respectively. 
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Table 1. NMR data of 1a and 2a in CDCl3.[a] 
 
Position 
SRB1a (1a) SRB2a (2a) 
δC (mult.)[b] δH (mult., J [Hz])[b] δC (mult.)[b] δH (mult., J [Hz])[b] 
1 171.4/171.5 (s) - 171.4/171.5 (s) - 
2 129.9/130.0 (s) - 129.9/130.0 (s) - 
3 157.6/157.6 (d) - 157.6/157.7 (d) - 
4 98.7/98.9 (d) 5.85 (brs) 98.7/98.9 (d) 5.85 (brs) 
5 11.5/11.6 (d) 2.07/2.09 (s) 11.5/11.6 (q) 2.08/2.09 (s) 
1’ 66.4/66.5 (d) 4.49 (m) 66.4/66.5 (d) 4.48 (m) 
2’ 35.6/35.7 (t) 1.70-1.85 (m) 35.5/35.7 (t) 1.70-1.85 (m) 
3’ 24.7/24.8 (t) 1.25, 1.36 (m) 24.7/24.8 (t) 1.22, 1.35 (m) 
4’ 23.0/23.1 (t) 1.53 (m) 23.0/23.2 (t) 1.53 (m) 
5’ 42.7/42.9 (t) 2.40 (dt, 3.4, 7.1) 42.7/42.9 (t) 2.40 (m) 
6’ 211.6/212.5 (s) - 211.8/212.8 (s) - 
7’ 51.9/52.0 (t) 2.26 (d, 7.1)  50.0/50.1 (t) 2.18 (dd, 7.9, 8.3), 
2.37 (m) 
8’ 24.7 (d) 2.09 (m) 30.9 (d) 1.90 (m) 
9’ 22.5/22.6 (d) 0.89 (d, 6.8)[c] 29.5 (t) 1.18, 1.28 (m) 
10’ - - 11.3 (q) 0.87 (d, 6.7) 
9’’ 22.5/22.6 (d) 0.90 (d, 6.7)[c] 19.3/19.4 (q) 0.86 (d, 7.0) 
[a] Spectra were recorded at 500 MHz for 1H and 125 MHz for 13C. [b] The residential solvent signal (δC 77) and internal standard tetramethylsilane 
(δH 0) were used as a reference. [c] Assignments are exchangeable. 
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Figure and Scheme Legends 
 
Figure 1. Spectral analysis of natural SRBs. A) Chiral HPLC analysis. Elution profiles 
were monitored by UV absorbance at 210 nm. B) ESI-MS spectrum. C) 1H NMR 
spectrum. D) HMBC spectrum and the key crosspeaks. E) 1H-1H COSY and HMBC 
correlations I) in the butenolide moiety of SRBs, II) in the C10 alkyl chain moiety of 
SRB1, and III) in the C11 alkyl chain moiety of SRB2. The δH and δC values were 
shown in underlined and italics, respectively. 
 
Figure 2. Determination of the C-1’ configuration of natural SRBs. A) Chiral HPLC 
analysis of I) natural SRBs (1 and 2), II) co-injection of natural SRBs and synthetic 1a, 
III) co-injection of natural SRBs and synthetic 2a, IV) synthetic 1a, V) 1b, VI) 2a, and 
VII) 2b. Elution profiles were monitored by UV absorbance at 210 nm. B) 1H NMR 
spectra of I) natural SRBs, II) synthetic 1a, and III) 2a (δH 0.75-2.50). 
 
Figure 3. Effect of SRB1 and SRB2 on lankacidin and lankamycin production. A) TLC 
analysis of metabolites. I) Parent 51252; II) strain KA20; III) strain KA20 supplemented 
with 1a (840 nM); IV) strain KA20 supplemented with 2a (840 nM). Lane LC is a 
standard sample of lankacidin C. B) HPLC analysis of metabolites. Elution profiles 
were monitored by UV absorbance at 230 nm. Closed diamonds and circle indicate the 
peaks of lankacidin C and lankacidinol A respectively. 
 
Scheme 1. Structures of Streptomyces signaling molecules. A) The known signaling 
molecules. 2,3-disubstituted γ-butyrolactone-type; A-factor, SCB1, SCB3, virginia 
butanolide A. Furan-type; methylenomycin furan. 4-monosubstituted butenolide-type; 
avenolide. B) Novel 2,3-disubstituted butenolides SRB1 (1) and SRB2 (2) isolated from 
S. rochei 7434AN4. 
 
Scheme 2. Synthesis of S. rochei butenolides A) SRB1 and B) SRB2. a) pyridinium 
chlorochromate, CH2Cl2; b) isobutylmagnesium bromide, THF; c) TMSO(CH2)2OTMS, 
TMSOTf, CH2Cl2; d) H2, 10% Pd-C, EtOAc; e) LDA, THF-HMPA, and then 7; f) 
BBr3, CH2Cl2; g) (S)-(2-methylbutyl)magnesium chloride, THF; h) LDA, THF-HMPA, 
and then 12. 
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Table of Contents text 
 
Butenolide signaling molecules in Streptomyces: Two signaling molecules, SRB1 and SRB2, that 
induce production of lankacidin and lankamycin in Streptomyces rochei 7434AN4 were isolated, and 
structure-determined. Both contain a 2,3-disubstituted γ-hydroxybutenolide skeleton, and the 
stereochemistry of C-1’ is crucial for inducing activity. 
 
